Hereditary Diffuse Gastric Cancer Clinical Trial
Official title:
Single-bite Versus Double-bite Technique for Mapping Biopsies During Endoscopic Surveillance of Hereditary Diffuse Gastric Cancer: a Single Center, Randomized Controlled Trial
Germline mutation in e-cadherin gene (CDH1) is found in approximately 25% to 30% of individuals fulfilling the clinical criteria for hereditary diffuse gastric cancer (HDGC). Prophylactic gastrectomy is the mainstay of the management of cases with pathogenetic CDH1 mutation. However, some individuals refuse gastrectomy and prefer to delay it for medical or psychosocial reasons. For these patients as well as for those in which a pathogenetic mutation is not found, endoscopic surveillance is recommended. The suggested endoscopic protocol involves targeted as well as 30 random biopsies, which is tedious and time-consuming . In order to save time, two specimens can be taken during a single passage of the biopsy forceps ("double-bite" technique). The aim of this study was to determine the adequacy and utility of the "double-bite" technique in patients undergoing surveillance for HDGC as compared to the standard "single-bite technique".
Previous studies have validated endoscopy, as an efficient tool for initial screening and in
selected cases surveillance of families fulfilling the clinical criteria for hereditary
diffuse gastric cancer (HDGC). The aim is to detect microscopic foci of in situ or
intramucosal signet ring cell carcinoma (SRCC), which are characteristic of early HDGC.
Currently, the recommended endoscopic protocol involves targeted biopsies of any suspicious
lesion as well as a minimum of 30 mapping random biopsies specimens taken from all anatomic
areas of the gastric mucosa, also known as Cambridge endoscopy protocol. However this is a
time-consuming and tedious process, which significantly prolongs the duration of the
procedure and might reduce patient tolerance. In order to save time two specimens can be
taken during a single passage of the forceps ("double-bite" technique).
In order to evaluate the adequacy and utility of the "double-bite" technique, patients
undergoing surveillance for HDGC, are randomized to the single-bite vs double-bite arm.
Endoscopies are performed according to a standardized protocol. Briefly, a white-light
high-resolution endoscope with 85 magnification and a maximal resolution of 7.9 mm
(GIF-FQ260Z; Olympus, Tokyo, Japan) is used to examine all anatomic segments of the
insufflated stomach. Any abnormalities on white-light endoscopy are recorded and assessed
further by narrow-band imaging magnification with or without autofluorescence imaging.
Targeted biopsy specimens are taken from identified lesions, and 5 random biopsy specimens
are taken in each of the siz gastric anatomical areas (prepylorus, antrum, transitional zone,
body, fundus, and cardia). The double-bite technique involves taking an initial biopsy,
repositioning the forceps, and taking another biopsy from the same area with the initial
specimen still on the forceps. The single bite technique involves removing the forceps with
its specimen after each individual biopsy. Time is recorded between the first and last random
biopsy. Comfort score is reported after the procedure, according to the modified Gloucester
scale. The investigators use Boston Single-Use Radial Jaw™ 4 biopsy forceps with a spike.
Biopsy specimens are stained with hematoxylin and eosin and periodic acid-Schiff diastase and
are assessed for size and presence of SRCC foci by an upper specialist GI pathologist, who
have significant experience in SRCC identification. Any lesions are checked by a second
pathologist within the Cambridge Pathology team before reporting. Both pathologists are
blinded to study arm.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04253106 -
Liquid Biopsies for the Personalized Management of Patients With Hereditary Diffuse Gastric Cancer
|
N/A | |
Recruiting |
NCT06163365 -
Inherited Cancer Early Diagnosis (ICED) Study
|
||
Completed |
NCT00633607 -
Hereditary Colorectal and Associated Tumor Registry Study
|
N/A |